Pfizer Inc. $PFE Holdings Raised by First Horizon Advisors Inc.

First Horizon Advisors Inc. lifted its stake in shares of Pfizer Inc. (NYSE:PFE) by 9.0% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 899,279 shares of the biopharmaceutical company’s stock after purchasing an additional 74,235 shares during the quarter. First Horizon Advisors Inc.’s holdings in Pfizer were worth $21,799,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also modified their holdings of the company. GKV Capital Management Co. Inc. bought a new stake in shares of Pfizer during the first quarter valued at about $27,000. Curio Wealth LLC raised its position in Pfizer by 36,600.0% in the second quarter. Curio Wealth LLC now owns 1,101 shares of the biopharmaceutical company’s stock worth $27,000 after acquiring an additional 1,098 shares in the last quarter. Bayforest Capital Ltd bought a new stake in Pfizer in the first quarter worth about $28,000. Harbor Asset Planning Inc. bought a new stake in Pfizer in the second quarter worth about $29,000. Finally, WPG Advisers LLC bought a new stake in Pfizer in the first quarter worth about $35,000. 68.36% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of equities analysts recently weighed in on the company. Sanford C. Bernstein reissued a “market perform” rating and issued a $30.00 price target on shares of Pfizer in a research note on Friday. Wall Street Zen cut Pfizer from a “buy” rating to a “hold” rating in a research report on Sunday, September 28th. Citigroup upped their target price on Pfizer from $25.00 to $26.00 and gave the stock a “neutral” rating in a research report on Wednesday, August 6th. Bank of America increased their price objective on Pfizer from $28.00 to $30.00 and gave the company a “neutral” rating in a research report on Friday, October 3rd. Finally, UBS Group restated a “neutral” rating and issued a $28.00 target price on shares of Pfizer in a research note on Wednesday, October 1st. One equities research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, twelve have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $28.24.

Pfizer Price Performance

Shares of PFE opened at $24.32 on Wednesday. The stock has a market cap of $138.24 billion, a P/E ratio of 12.93, a price-to-earnings-growth ratio of 0.81 and a beta of 0.54. The company has a current ratio of 1.16, a quick ratio of 0.85 and a debt-to-equity ratio of 0.65. The stock’s 50-day moving average price is $24.75 and its two-hundred day moving average price is $24.33. Pfizer Inc. has a 1 year low of $20.92 and a 1 year high of $28.00.

Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, November 4th. The biopharmaceutical company reported $0.87 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.79 by $0.08. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.The business had revenue of $16.65 billion for the quarter, compared to analyst estimates of $16.94 billion. Pfizer has set its FY 2025 guidance at 3.000-3.150 EPS. On average, equities analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Monday, December 1st. Investors of record on Friday, November 7th will be paid a $0.43 dividend. The ex-dividend date is Friday, November 7th. This represents a $1.72 annualized dividend and a yield of 7.1%. Pfizer’s payout ratio is 91.49%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.